Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Curis, Inc.

Curis, Inc is focused on developing innovative therapeutics for the treatment of cancer, specifically targeting hematologic malignancies and other cancers. This includes their marketed product, Erivedge, and several drugs in their pipeline.

msh id	COM:CURIS
symbol	CRIS
name	Curis, Inc.
homepage url	https://www.curis.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	49
crunchbase url	-
linkedin url	-
founders	-

market cap	40.49M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	1.77K
monthly webtraffic growth	-0.41
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.08
growth cost of revenue	-1
growth depreciation and amortization	-1
growth ebitda	0.09
growth ebitda ratio	0.08
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.05
growth gross profit	0.01
growth gross profit ratio	0.03

COM:CURIS

Curis, Inc

Last Close

3.70

21/11 21:00

Market Cap

40.49M

Beta: -

Volume Today

87.95K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	58.36M
cost of revenue	58.36M
depreciation and amortization	-
ebitda	-48.33M
ebitda ratio	-4.82
eps	-0.01
eps diluted	-0.01
operating expenses	58.36M
operating income	-48.33M
operating income ratio	-4.82

accounts receivables	181K
capital expenditure	-
cash at beginning of period	20.29M
cash at end of period	27.23M
inventory	-
working capital ttm	64.65M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-